Loading...
First-line treatment of women with advanced ovarian cancer: focus on bevacizumab
Ovarian cancer is the fifth most common cause of cancer death in women in Europe. Despite the progress, almost 70% of the patients relapse. The standard treatment is cytoreductive surgery followed by platinumtaxane chemotherapy; in patients with a disseminated disease, one option is neoadjuvant chem...
Na minha lista:
| Udgivet i: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6371937/ https://ncbi.nlm.nih.gov/pubmed/30799939 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S155425 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|